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Introductionthrough 24 hours post-transplantation and have initiated transplants for later time points. We have characterized these transplants with a series of markers to begin to define their behavior.
Our initial experimental protocol called for Brdu injection and tissue harvest at 6 hour intervals. We have modified this protocol for the first 24 hours such that BrdU injection and tissue harvest have been performed at 4 hour intervals after transplantation. This change was instituted because we were concerned that we might miss critical early and/or transient events in the regenerative process. Our concerns appear to be well-founded.
Figure 1.
Changes in proliferation and marker expression during early mammary gland regeneration. Timepoint at harvest is denoted to the left of the row to which it applies. Marker assayed is denoted above the column to which it applies. Green arrows denote cells stained positively for BrdU incorporation with co-expression of Ki67. Magenta arrows denote cells expressing Ki67 exclusively. White arrow denotes an area of cells in which E-cadherin expression is reduced or lost.
Early regeneration appears to occur in a defined series of events. At 4 hours, there is a small burst of DNA synthesis in which ~2% of all epithelial cells in the transplant initiate DNA synthesis as determined by incorporation of BrdU and co-expression of Ki67 ( Figure 1A ). In addition, other cells enter the cell cycle based on expression of Ki67 alone ( Figure 1A ). At 8 hours, most cells expressing Ki67 also stain positive for incorporation of BrdU ( Figure 1D ). After this point, there is an approximately 16 hour period of relative growth quiescence ( Figure 1G ), followed by a second burst of proliferation at ~24 hours ( Figure 1J ). At this time ~15% of epithelial cells stain positively for expression of the Ki67 proliferation marker.
We also observed transient changes in gene expression in the myoepithelial cell layer. While all myoepithelial cells appear to express p63 at 4 hours ( Figure 1B) , at 8-20 hours, we observed reduction or loss of p63 expression in the myoepithelial cells (Figure 1E and 1H) , which begins to be re-expressed at the 24 hour timepoint ( Figure 1K ). This loss of p63 expression was not due to caspase-3 mediated apoptosis since we did not observe apoptotic cells in any of the transplanted fragments examined.
In the luminal cell layer, while epithelial cells at 4, 8 and 23 hours expressed E-cadherin in a relatively uniform pattern in all luminal epithelial cells ( Figure 1C , 1F, and 1L), we observed transient reduction in the percentage of cells expressing E-cadherin, particularly at 12 hours ( Figure  1I ), with evidence to suggest reorganization of the epithelial cells within some of the transplanted fragments at the 12-24 hour timepoints.
Our interpretation of these data is that cells undergoing early DNA synthesis likely represent division-competent cells arrested at the G1/S restriction point of the cell cycle that, upon transplantation, were released from this cell cycle block and allowed to enter S-phase. Cells expressing Ki67 alone may have exited G0, but have not yet initiated DNA synthesis. By 8 hours, most of the Ki67+ cells have entered S-phase. These cells are most likely to be the same ERprogenitor cell types that one observes dividing in the mature gland normally, but are unlikely to represent true regenerative stem cells. Upon cellular reorganization, cells undergoing late DNA synthesis most likely represent regenerative stem cells and division-competent progenitor cells initiating the regeneration process. We are currently evaluating potential markers that might distinguish early and late S-phase cells from one another and from non-dividing cell types.
Loss of p63 expression from the myoepithelial cells and reduction/loss of E-cadherin expression from luminal epithelial cells was unexpected and indicates a degree of plasticity of both cell types. It is possible that both events influence the regeneration process. Thus, it would be of interest to see how sustained expression of either protein affected early regeneration. Our prediction is that sustained expression would delay onset of regeneration.
There are a number of technical limitations to these studies that we are attempting to overcome. The primary limitation is the small number of cells present in the transplanted fragments. The small size of the transplants makes them exceptionally difficult to find for conducting immunofluorescence analysis. We are therefore using epithelium genetically tagged to express enhanced cyan fluorescent protein (ECFP), which affords the opportunity to localize the transplanted duct fragment roughly within a given gland. We have begun to use 0.5mm skin biopsy punches to isolate the region containing the transplanted fragment coupled with use of tissue microarrays of multiple fragments from a given timepoint to enhance our ability to characterize regeneration events.
In addition to the difficulty in localizing transplanted epithelium, the small fragment size means that samples are exhausted quickly during microtomy, thus requiring numerous transplants for each timepoint. Finally, while putative stem cell markers have been published recently, all putative stem/progenitor cell markers used currently rely on subtle differences in fluorescence intensity in flow cytometric analysis using thousands of cells. Flow cytometric analysis is not possible for small fragments such as those being analyzed in this study (n<1000 cells/fragment). Thus, new markers are required that can be used in immunofluorescence analysis. We are attempting to identify such markers using a candidate gene approach.
Mammosphere-formation and Limiting-dilution transplantation: In addition, to the fragment transplantation experiments, we have spent considerable effort to optimize mammosphereformation and limiting dilution transplantation protocols for analysis of stem cell function in both wild type and mutant mice. We have used these techniques to compare stem cell function in FVB mice and our new MMTV-SmoM2 mice expressing a constitutively activated form of Smoothened, the main effector of activated hedgehog signaling.
To determine whether MMTV-SmoM2 transgenic mice showed a change in the frequency of mammosphere-forming cells relative to wild type controls, we conducted primary mammosphereformation assays . Using normal human mammary epithelial cells, mammospheres can be produced both by cells with multilineage differentiation capacity (a surrogate test for stem cells, presumably having regenerative potential), as well as by division-competent cells with either luminal or myoepithelial differentiation capacity (presumably lacking regenerative potential). In four of five independent paired primary cell preparations, cells derived from MMTV-SmoM2 mice showed a ~2-fold increase in the percentage of cells capable of forming primary mammospheres (mean raw value = 0.76%) relative to cells isolated from wild type littermate control mice (mean raw value = 0.38%) (P=0.02, paired-t test) (Figure 2A and 2B ). There were no differences in mammosphere size or shape noted between the two genotypes ( Figure 2C ).
To verify that primary mammospheres contained regenerative mammary epithelial stem cells, we transplanted single mammospheres derived from wild type and MMTV-SmoM2 mice into contralateral cleared fat pads of three-week old host mice. Mammospheres derived from both genotypes showed regenerative potential, with 2/13 (15%) of wild type mammospheres ( Figure 2D , left panel), and 5/15 (33%) of MMTV-SmoM2 mammospheres ( Figure 2D , right panel) capable of regenerating ductal trees. These regeneration frequencies were not statistically different from one another (P=0.40, Fisher's exact test). Duct morphology in MMTV-SmoM2 outgrowths was consistently altered relative to wild type in a manner consistent with the phenotype observed in intact mice. Because mammosphere-formation assays are an indirect measure of the frequency of stem and progenitor cells present in the intact mammary gland, and because single mammosphere transplants showed no difference in regeneration frequency, it was possible that the two-fold increase in mammosphere-forming efficiency in cells derived from MMTV-SmoM2 mice might not be due to an increased proportion of regenerative stem cells in vivo, but rather due to an increase in the survival (or activity) of mammosphere-initiating cells under anchorage-independent growth conditions. To address this possibility, we conducted limiting dilution transplantation analysis designed to detect differences in the proportion of cells with regenerative capacity directly ( Figure  2E ).
We were fortunate enough to find a protocol quickly that allows for a transplant efficiently approximately one order of magnitude better than any published result (e.g. 1 regenerative stem cell per 1,400-2000 cells) -and is therefore in much better agreement with our fragment transplantation analyses. In this method, single cell suspensions of primary mammary epithelial cells are diluted into phosphate-buffered saline instead of tissue culture medium. After dilution, cells are mixed 1:1 (v/v) with Matrigel and injected in a 10ul volume. Injected glands are harvested 8 weeks posttransplantation and evaluated for growth of mammary glands.
For both genotypes, as few as 25 cells were capable of regenerating ductal trees. However, the rate of successful transplantation, or "take rate", was lower in cells derived from MMTV-SmoM2 mice below 200 cells/gland injected. Using a single-hit Poisson distribution model , we estimate the frequency of regenerative stem cells in wild type epithelium is 1 stem cell per 106 cells ( Figure 2E ). The frequency of regenerative stem cells in MMTV-SmoM2 epithelium was decreased ~2.5 fold, to 1 stem cell per 255 cells. Again, duct morphology in MMTV-SmoM2 outgrowths was consistently altered relative to wild type ( Figure 2F) .
A manuscript summarizing these results has been submitted for publication to Development as part of our analysis of a new transgenic mouse model for hedgehog signaling activation (MMTVSmoM2) (see below) and is currently under review.
Objective 2) To develop the short-term transplantation assay as a means by which critical regulators of stem and progenitor cell behavior can be discovered and evaluated.
Based on our optimized results from Objective 1, we are now in the position to be able to test our hypothesis rigorously using tissue fragments and cells derived from the MMTV-Wnt1 transgenic mouse model, as well as our new MMTV-SmoM2 transgenic mouse model (constitutively activated hedgehog signaling) (Moraes et al. submitted to Development). The MMTV-Wnt1 model was shown to possess an increased number of regenerative stem cells by limiting-dilution transplantation (though using a different method than that developed by us). Our MMTV-SmoM2 model shows an increase in the proportion of mammosphere-initiating cells (stem and progenitor cells), but a decrease in the proportion of regenerative stem cells in our optimized limiting-dlilution transplantation assay (Moraes et al. submitted to Development). Thus, we will have two bona-fide mouse models with which to test our initial hypothesis -one that increases regenerative capacity, and one that decreases regenerative capacity.
Key research accomplishments
1. Temporal characterization of early mammary gland regeneration through 24 hours with respect to BrdU incorporation and Ki67 expression. 2. Discovery of phenotypic plasticity of both luminal and myoepithelial cells during early regeneration with respect to p63 expression (myoepithelium) and E-cadherin expression (luminal epithelium), which offers some mechanistic insight into the early regeneration process since p63 is essential for mammary gland growth. 3. Optimization of limiting dilution transplantation and refinement of the estimate for the frequency of regenerative stem cells in the wild type gland relative to a new transgenic mouse line, MMTV-SmoM2, which shows a two-fold depletion in the frequency of regenerative stem cells. 4. Formal demonstration that about 1/3 of mammospheres contain, and therefore arise from, regenerative stem cells.
5. Formal demonstration that the mammosphere assay underestimates the true frequency of regenerative stem cells in the mouse mammary gland. 
Conclusions
Short-term transplantation appears to give a better estimate of the frequency of divisioncompetent cells present in the gland than traditional assays. If suitable markers can be identified that can distinguish regenerative stem cells from downstream progenitor cells, the short-term transplantation assay may be a useful and rapid method for quantifying changes in the relative proportion of these cells due to mutation or treatment with bioactive compounds.
Analysis of the first events of mammary gland regeneration should allow identification of regulatory signaling networks and other regulatory mechanisms that govern stem and progenitor cell self-renewal.
INTRODUCTION
The hedgehog signaling network regulates pattern formation, proliferation, cell fate, and stem/progenitor cell maintenance and self-renewal in many organs (Cohen, 2003; Hooper and Scott, 2005; Lewis and Veltmaat, 2004; Nusse, 2003) . Genetic analyses in mice indicate a role in mammary ductal morphogenesis, and recent data suggest a role in human mammary epithelial stem cell selfrenewal (Liu et al., 2006) . In addition to hedgehog functions in normal development, altered hedgehog signaling is now implicated in approximately 20-25% of all cancers (Briscoe and Therond, 2005) , and there is increasing evidence to suggest a role in breast cancer (Chang-Claude et al., 2003; Kubo et al., 2004; Lewis et al., 2001; Lewis et al., 1999; Liu et al., 2006; Mukherjee et al., 2006; Naylor et al., 2005) . However, the specific roles hedgehog network genes play in normal mammary gland development remain unclear, and no experiments have been performed to test directly whether inappropriately activated hedgehog signaling has functional consequences for gland development, or causes breast cancer.
Development of the mouse mammary gland begins in the embryo with formation of a rudimentary ductal tree, but most development occurs after puberty (Daniel, 1987; Sakakura, 1987) . At puberty, ovarian steroids stimulate rapid and invasive ductal elongation and branching morphogenesis.
At the growing tips of elongating ducts are bulb-like structures called terminal end buds (TEB).
Histologically, TEBs consist of two highly proliferative cell compartments, an outer "cap cell" compartment, and an inner "body cell" compartment consisting of 4-6 layers of relatively undifferentiated luminal epithelial cells. As the TEB invades the mammary fat pad, cap cells serve as a progenitor cell population and differentiate into myoepithelial cells that line the basement membrane (Williams and Daniel, 1983) , while body cells are thought to give rise to all luminal epithelial cell subtypes, including new multipotent mammary stem cells, of the mature duct. As ducts elongate, they are surrounded by a periductal stroma consisting of fibroblasts, macrophages, eosinophils, and vascular cells, within the confines of the mammary fat pad. releases inhibition of SMO, which leads to induction of target genes by transcriptional activator forms of Gli transcription factors (GLI1, GLI2, or GLI3). In addition to its signal transduction activities, PTCH1 can also function to sequester hedgehog ligand, thereby restricting the range over which free ligand can signal (reviewed in (Hooper and Scott, 2005) ). Finally, there is evidence to suggest PTCH1 can function as a "dependence receptor" to induce apoptosis in cell types dependent on ligand-bound PTCH1 for survival (Chao, 2003; Guerrero and Ruiz i Altaba, 2003; Thibert et al., 2003) .
Our laboratory previously demonstrated critical functions for Ptch1 and Gli2 in mammary ductal development (Lewis et al., 2001; Lewis et al., 1999; Lewis and Veltmaat, 2004) . Heterozygous mutation of Ptch1 (∆Ptch1/+) led to ductal dysplasia in virgin mice characterized by multiple epithelial cell layers within the ducts (Lewis et al., 1999) . Similarly, transplantation rescue of whole mammary glands from homozygous Gli2-null mouse embryos yielded ductal dysplasias (Lewis et al., 2001 ).
However, for both Ptch1 and Gli2, transplantation of mutant epithelium into a wild type stroma failed to recapitulate the phenotype observed in intact glands, suggesting that these two genes function primarily in the stroma to regulate epithelial cell behavior. Thus, despite developmentally regulated hedgehog network gene expression in the epithelial compartment (Lewis et al., 2001 ) a role for activated hedgehog signaling in the epithelium has not been demonstrated during ductal development (Gallego et al., 2002; Michno et al., 2003) , and the consequences of inappropriate hedgehog signaling in the epithelium are not known. Our published working model for hedgehog signaling in mammary ductal development (Lewis and Veltmaat, 2004) proposes that hedgehog signaling may function transiently in the body cell layer of the TEB, but that signaling must be prevented in differentiated ducts. Consistent with this hypothesis, Liu and colleagues (Liu et al., 2006) showed that treatment of human breast epithelium with recombinant hedgehog ligand increased both primary and secondary mammosphere formation (in vitro assays of anchorage-independent growth, and of self-renewal of stem and progenitor cell types ), while treatment with the hedgehog signaling antagonist cyclopamine decreased mammosphere formation. In this paper, we examine the effect of sustained SMO-mediated hedgehog signaling during ductal elongation in virgin transgenic mice, and correlate our results with altered PTCH1 and SMO expression in human breast cancer. Taken together, our results are consistent with a role in mammary epithelial progenitor cell regulation, and suggest that ectopic hedgehog signaling may contribute to human breast cancer by stimulating proliferation, and by increasing the pool of division-competent cells capable of anchorage-independent growth. Matthew Scott (Stanford University), and were maintained by backcrossing to B6D2F1 mice.
MATERIALS AND METHODS

Generation of MMTV-SmoM2
Genotype determination for the Ptch1 disruption allele was performed as described previously (Lewis et al., 1999) . All mice were maintained in accordance with the NIH Guide for the Care and Use of Experimental Animals with approval from our Institutional Animal Care and Use Committee. Whole gland morphological analysis: Mammary glands #1-5 were harvested from the right side of at least 10 female mice at 5 and 10 weeks of age, as well as at >70 weeks of age (palpated weekly after 52 weeks of age to assay for tumor development), fixed in ice-cold 4% paraformaldehyde:PBS, and examined as whole mount preparations using a neutral red staining protocol. After fixation, fat was removed in three changes of acetone (1 hour each) and glands were stained in neutral red staining solution (0.01% neutral red in 100% EtOH acidified to pH 5.0 with glacial acetic acid) overnight with constant stirring. Glands were de-stained in 2 changes of 100%
EtOH, cleared in two changes of xylenes (1 hour each), and stored in xylenes. Average terminal end bud (TEB) number per gland was quantified using the #3 mammary gland at 5 weeks of age. Branch point analysis and evaluation of retained TEB-like structures were conducted using the #3 mammary gland at 10 weeks of age by direct counting of all branchpoints.
Immunohistochemistry and immunofluorescence analysis:
For histological analysis, the #2 and #3 mammary glands from the left side of the animal were fixed in 4% paraformaldehyde:PBS, embedded in paraffin, sectioned, and either hematoxylin/eosin stained or used for immunolocalization studies. Antibodies used for immunolocalization studies are listed in Table 1 . All immunostaining was performed with antigen retrieval in 0.1M Tris-HCl, pH 9.0 with 10% Tween-20, or in TRS (DakoCytomation), by heating to 120°C, 10 min. in a pressure cooker. For immunohistochemistry, detection was by standard peroxidase staining using the ABC system (Vector Laboratories). For immunofluorescence, sections were counterstained with DAPI in mounting medium (Vectashield).
Primary mammary epithelial cell isolation:
Primary mammary epithelial cells were isolated from freshly dissected mammary glands by enzymatic dissociation overnight in DMEM;Ham's F12 medium (5ml/mouse) containing collagenase (1mg/ml), hyaluronidase (100U/ml), penicillin/streptomycin (100U/ml), and gentamycin (50µg/ml) essentially as described (Smith, 1996) .
Resulting cell pellets were treated with 1ml 0.25% Trypsin-EDTA, 37°C, 5 minutes. Trypsin was inactivated with 10ml HBSS containing 5% serum. Cells were centrifuged and washed three times in HBSS+5% serum. After the final wash, each preparation was filtered through a 40µm strainer to yield a single cell suspension. Single cell suspensions were used directly in mammosphere-formation assays and limiting-dilution transplantation assays.
Mammosphere-formation and transplantation assays: Primary mammary epithelial cells derived from five paired sets of wild type or MMTV-SmoM2 mice (3-4 mice/genotype/set) were plated in triplicate wells of six-well ultra-low attachment plates (2ml/well) at a concentration of 30,000 cells/ml as described previously Youn et al., 2005) . Cells were fed every 3-4 days for 10-14 days for mammospheres to form. Primary mammospheres were counted for each genotype, and the percentage of mammosphere-forming cells was calculated as a measure of mammosphere-
forming efficiency.
To demonstrate that mammospheres contained stem cells capable of regenerating ductal trees, single mammospheres derived from wild type and MMTV-SmoM2 mice were transplanted into contralateral cleared fat pads of three week old recipient FVB female mice (Deome et al., 1959) .
Transplanted mammospheres were allowed to grow for 6-8 weeks. Glands were then excised, fixed, and stained as whole mount preparations.
Limiting dilution cell transplantation assays: Primary mammary epithelial cells were isolated from 10 week old wild type and MMTV-SmoM2 female mice, and counted on a hemocytometer. Cells were resuspended in a 1:1 solution of PBS:Matrigel (BD Biosciences 354234) at the desired concentration, and kept on ice until transplantation. Cells of each genotype were injected at limiting dilutions (1000, 500, 200, 100, 50, and 25 cells/gland in a total volume of 10µl) into contralateral cleared fat pads of the #4 mammary glands of 21-day-old female wild type mice using a 25G needle attached to a 50µl Hamilton glass syringe (Deome et al., 1959) . Seven weeks after transplantation, #4
glands and a #3 host control gland were excised and stained as whole mounts. Glands showing ≥5% fat pad filling were scored as a positive "take".
Human breast clinical samples: Low density tissue arrays comprised of archival formalinfixed, paraffin-embedded samples of either ductal carcinoma in situ (DCIS), invasive breast cancer (IBC), or normal tissue derived from patients with breast cancer were used. All tissue was obtained, and used, with approval from our Institutional Review Board. DCIS samples had been scored previously for histological grade. Both DCIS and IBC samples had been scored previously for expression of estrogen receptor alpha (ERα), HER2/ERBB2, and p53 by the method of Allred (Allred et al., 1998; Harvey et al., 1999) , in which a total score (0-8) is assigned as the sum of the proportion score (0-5), and an intensity score (0-3) for the expression of a given gene.
Quantitative RT-PCR: Total RNA was extracted using Trizol Reagent (Invitrogen). Total RNA (100ng/sample in triplicate) was reverse-transcribed (M-MLV Reverse Transcriptase, Invitrogen)
following the manufacturer's protocol, and the resulting cDNA was analyzed using the Applied Biosystems 7500-Fast thermocycler for TaqMan® quantitative PCR (Q-PCR), using standard conditions. TaqMan® Assay On Demand primers and probes were purchased from Applied
Biosystems. Product accumulation was evaluated using the comparative Ct method (∆∆Ct Method), with beta-actin as an endogenous control for normalization (Livak and Schmittgen, 2001 ). Regeneration frequencies were compared using Fisher's exact test.
Limiting dilution analysis was performed to estimate the frequency of regenerative stem cells in primary mammary epithelial cell preparations, along with 95% Wald confidence intervals (Smyth, 2006) . The single-hit Poisson model (SHPM) was fitted to limiting dilution data using a complementary log-log generalized linear model .
In human clinical samples, correlations between expression of PTCH1 or SMO and clinicallyrelevant markers in DCIS, as well as that between PTCH1 and SMO in DCIS and IBC, were tested for statistical significance using Spearman's rank correlation. All of the variables in the correlation analysis were analyzed as continuous variables. Immunohistochemical total scores for expression of PTCH1 and SMO were compared between normal, DCIS, and IBC tissues using the Wilcoxon ranksum test. Statistical analyses were performed with SAS (version 9.1), S-PLUS (version 7.0), or R (version 2.2.1). P-values of 0.05 or less were deemed statistically significant.
RESULTS
Ectopic SMO expression leads to mammary dysplasia in transgenic mice. Our working model of hedgehog network regulation of mammary ductal development proposes that the hedgehog signaling network may be active transiently in body cells of the TEB, but that signaling must be prevented in the epithelium of differentiated ducts (Lewis and Veltmaat, 2004) . Thus, we hypothesized that constitutive activation in the epithelium might lead to altered ductal development, altered differentiation, and, perhaps, tumor formation. To test these hypotheses, we generated transgenic mice expressing a constitutively activated form of human SMO (Xie et al., 1998) selectively in mammary epithelium under the control of the MMTV promoter (Tg(MMTV-SmoM2)).
In whole mount analysis, glands of wild type mice at 5 weeks of age showed normal morphology of TEBs and subtending ducts ( Figure 1A ). In contrast, TEBs of MMTV-SmoM2 mice frequently displayed excessive budding at the neck of the TEB ( Figure 1B ) and an increase in TEB number ( Figure 1C ) (P=0.05). In histological analyses, wild type glands showed normal TEB structure ( Figure 1D ). In contrast, ~30% of TEBs in MMTV-SmoM2 glands showed disorganized cap and body cell layers ( Figure 1E ).
At 10 weeks of age, wild type ducts showed simple patterning and duct structure ( Figure 1F ).
In contrast, MMTV-SmoM2 transgenic mice showed one or more glands with enhanced side budding ( Figure 1G ) and increased branching by branch point analysis ( Figure 1H ) (P=0.04). Approximately 60% of transgenic mice showed retention of TEB-like structures ( Figure 1G , inset, and Figure 1H ).
At 10 weeks of age, ducts of wild type glands ( Figure 1I ) showed normal histoarchitecture with a single layer of lumenal epithelium and a single layer of myoepithelium. Ducts of MMTV-SmoM2 glands showed histology consistent with increased side-budding, but appeared normal with respect to the lumenal and myoepithelial cell layers ( Figure 1J ), and did not show ducts having multiple layers of lumenal epithelium characteristic of ∆Ptch1/+ mice ( (Lewis et al., 1999) and Figures 3E and 3F ).
Retained TEB-like structures showed histoarchitecture similar to TEBs, but the body cell layer was generally only 2-4 cell layers thick ( Figure 1J, inset) . No tumors were detected in aged wild type virgin mice (n=15), and only a single tumor was detected in a cohort of aged transgenic virgin mice (n=77).
Our 
PTCH1 loss and SMO activation increase proliferation in the mammary gland in vivo.
We next compared BrdU incorporation rates and expression patterns for cleaved caspase-3, ER, and PR, using glands of 10 week old MMTV-SmoM2, ∆Ptch1/+, and wild type control mice ( Figure 3 and Table 1 Supplemental). We detected no change in ER or PR expression between wild type and either
MMTV-SmoM2 or ∆Ptch1/+ mice, but detected a significant increase in BrdU incorporation in both
MMTV-SmoM2 (4.4%) and ∆Ptch1/+ mice (11.3%) relative to wild type age-matched littermate controls (~0.6%) ( Figure 3A vs.
3C and 3E). Elevated BrdU incorporation rates in MMTV-SmoM2
glands were corroborated by Ki67 staining, which was detected in 6.2% of wild type cells ( Figure 3A inset), but in 31.3% of cells in MMTV-SmoM2 glands ( Figure 3C inset, and Table 1 Supplemental) .
Because the MMTV-SmoM2 mutant did not recapitulate the ∆Ptch1/+ phenotype, we expected to observe a compensatory increase in cell death to offset increased proliferation. Wild type glands showed low levels of cleaved caspase-3 staining (<1%) ( Figure 3B ). Contrary to expectations, MMTVSmoM2 mice did not show increased caspase-3-mediated apoptosis ( Figure 3D ). Glands from ∆Ptch1/+ mice also showed no change in cleaved caspase-3 expression as a percentage of total epithelial cells ( Figure 3F ). Thus, the reason proliferating cells accumulate in glands of ∆Ptch1/+ mice, but do not accumulate in glands of MMTV-SmoM2 mice, remains unclear.
MMTV-SmoM2 transgene expression and proliferation do not colocalize. The observation that SMO expression was limited, yet morphological defects and expression of proliferation markers
were wide-spread, led us to question to what degree transgene expression correlated with proliferation and hormone receptor status. We therefore conducted dual immunofluorescence staining for SMO, Ki67, and ER, and quantified co-expression in pairwise combinations. Overall, SMO was expressed in 5.7% of all epithelial cells, while Ki67 was expressed in 31.3% of epithelial cells. However, SMO and Ki67 did not colocalize ( Figure 4A ). We also found that SMO expression did not colocalize with ER ( Figure 4B ), with 33.0% of cells showing ER expression exclusively. Unlike wild type glands, ER and Ki67 colocalized at a low, but measurable, frequency (1.0%) in glands of transgenic mice ( Figure 4C ), (Table 1 Supplemental) . Proliferation in ER-positive cells was confirmed by co-staining for ER and BrdU ( Figure 4C , inset).
MMTV-SmoM2
mice show altered epithelial cell differentiation. Cytokeratin 6 (CK6), a marker of primitive progenitor cells (Grimm et al., 2006; Stingl et al., 2005) , is expressed primarily in ER-positive cells in the body cell layer of the TEB, and only rarely in differentiated ducts of mature 13 glands (Grimm et al., 2006) . As expected, in mature ducts of 10 week old wild type mice, expression of SMO was undetectable and CK6 was observed infrequently (7.5%), and at very low levels (Table 1 Supplemental). However, in 10 week old MMTV-SmoM2 mice, CK6 expression was readily detectable in ~20% of epithelial cells ( Figure 4D and 4E) . Co-staining of CK6 and ER demonstrated that the majority of CK6+ cells (82.0%) were also ER+ ( Figure 4D ). There was no co-localization of SMO with CK6 ( Figure 4E with inset) . Thus, the MMTV-SmoM2 transgene was expressed to detectable levels only in non-proliferative ER-CK6-cells.
MMTV-SmoM2 increases the proportion of mammosphere-forming cells in mammary glands of transgenic mice in vivo.
To determine whether MMTV-SmoM2 transgenic mice showed a change in the frequency of mammosphere-forming cells relative to wild type controls, we conducted primary mammosphere-formation assays Figure 5A and 5B). There were no differences in mammosphere size or shape noted between the two genotypes ( Figure 5C ).
To verify that primary mammospheres contained regenerative mammary epithelial stem cells, consistently altered relative to wild type ( Figure 5F ).
Hedgehog signaling is altered at high frequency in human breast cancer. To evaluate a potential role for PTCH1 and SMO in human breast cancer, we conducted an immunohistochemical study for expression of PTCH1 and SMO in a panel of normal, DCIS, and IBC samples ( Figure 6 and Table 4 ). PTCH1 was detectable throughout the epithelium ( Figure 6A ), and in isolated stromal cells of the normal breast. In contrast, PTCH1 expression was decreased or absent in ~50% of ductal carcinoma in situ (DCIS) ( Figure 6B ) and invasive breast cancers (IBC) ( Figure 6C ). Conversely, SMO was undetectable in normal breast ( Figure 6D ), but ectopically expressed in ~70% of DCIS and ~30% of IBC ( Figures 6E and 6F 
DISCUSSION
In this paper, we show that expression of constitutively activated human SMO (SmoM2) under the MMTV promoter in transgenic mice leads to ductal dysplasias distinct from those caused by ∆Ptch1 heterozygosity, despite increased in proliferation in both models. SMO expression rarely colocalized with the Ki67 proliferation marker, and activation was not sufficient to cause tumors at high frequency. SMO activation led to altered differentiation, as well as enhanced primary mammosphere-forming efficiency. However, limiting-dilution transplantation analysis showed a decrease in the frequency of regenerative stem cells in MMTV-SmoM2 epithelium relative to wild type.
In human clinical samples, hedgehog network gene expression is altered frequently, and early, in breast cancer development. As in MMTV-SmoM2 mice, SMO rarely colocalized with Ki67 in breast tumors.
Taken together, these data are consistent with our model that hedgehog signaling must be prevented in mature ducts of virgin mice, and suggests that it is also inactive normally in mature ducts in humans.
Thus, ectopic hedgehog signaling could contribute to early breast cancer development by stimulating proliferation, and by increasing the pool of division-competent cells capable of anchorage-independent growth.
In light of our transplantation results published previously (Lewis et al., 1999) , failure of MMTV-SmoM2 to recapitulate the ∆Ptch1 hyperplastic phenotype was not entirely unexpected. In these experiments, the ∆Ptch1/+ phenotype could be partially recapitulated, but only when the entire mammary gland was transplanted --transplantation of epithelial fragments into cleared fat pads of wild type mice did not lead to ductal dysplasia. These results led to the interpretation that the ∆Ptch1/+ phenotype was due primarily to loss-of-function in mammary stroma. Since the MMTV-SmoM2 transgene is expressed selectively in the mammary epithelium, stromal activation of hedgehog signaling was not tested here. Thus, the two models are not directly comparable. However, our results clearly demonstrate that ∆Ptch1 heterozygosity is not functionally equivalent to SMO activation solely in mammary epithelium.
In 10 week old MMTV-SmoM2 mice, we demonstrate altered gland morphology in whole signaling functions for the estrogen and progesterone receptors during mammary gland development (Brisken et al., 1998; Mallepell et al., 2006) .
A second possibility is that SMO is expressed and active in >5.7% of cells, but that SMO protein expression is below the limit of detection. Consistent with this possibility, available antibodies must be used at relatively high concentrations, and fail to detect SMO in some tissues known have hedgehog signaling activity (e.g. E14 embryo, hair follicle, colon) (not shown). However, this interpretation requires the supposition that low-level activity is not sufficient to induce expression of PTCH1 in most cells (Hooper and Scott, 2005) (Figure 2 and Figure 1 Supplemental). Alternatively, it may be that the majority of mouse mammary epithelial cells are incompetent to respond to increased SMO activity. Indeed, with the exception of Hip1, whose expression by Q-PCR was increased 2-fold (p=0.049) above wild type, ∆Ptch1 heterozygosity was also not sufficient to induce expression of other hedgehog network genes (Figure 1, Supplemental) .
A third interpretation is that the primary effect of ectopic SMO expression occurs in, or near, the TEB and leads to a permanent alteration in cell fate. This would require that the permanent alteration lead to inactivation of the MMTV promoter such that it was no longer expressed. This possibility is being addressed using an conditional SMO overexpression model to activate signaling after ductal development is completed (Jeong et al., 2004) .
With respect to normal mammary development, our data and those of Liu et al. (Liu et al., 2006) are consistent with our working model in which hedgehog signaling may be active in the growing TEB (extrapolated from Ihh and Ptch1 in situ hybridization data showing low, but detectable expression of Ihh in the TEB, as well as increased Ptch1 expression relative to the immediately subtending differentiated duct), but that signaling is normally absent from mature ducts of the wild type mice (Lewis and Veltmaat, 2004) . Absence of activated hedgehog signaling in mature ducts is supported by reduced levels of Ptch1 mRNA in differentiated ducts relative to the TEB, the lack of detectable SMO protein expression, and the failure to detect Gli gene function in mammary epithelium of postnatal animals (Hatsell and Cowin, 2006; Lewis et al., 2001; Lewis and Veltmaat, 2004) . It remains possible that postnatal mammary duct formation is entirely hedgehog ligand-independent (discussed in (Lewis and Veltmaat, 2004) ). However, the definitive experiments required to determine whether active hedgehog signaling functions in the epithelium during postnatal ductal development have never been performed. We are currently analyzing conditional null mutants of both Ptch1 and
Smo, which should allow us to test our model conclusively.
In MMTV-SmoM2 mice, we observed a two-fold increase in the percentage of mammosphereforming cells present in primary mammary epithelial cell cultures relative to wild type Youn et al., 2005) . Unfortunately, a potential limitation of secondary mammosphere-formation assays for the evaluation of changes in self-renewal capacity in MMTV transgenic mice was revealed.
In our hands, transgene expression was not detectable in primary mammospheres by immunofluorescence (not shown). Because of this, secondary mammosphere-formation assays to test for changes in stem cell self-renewal as a consequence of transgene expression during primary mammosphere culture were not considered reliable. Thus, it is difficult to compare our mouse mammosphere-formation data directly with those of Liu et al (Liu et al., 2006) who demonstrated increased primary and secondary mammosphere formation in response to treatment with recombinant SHH ligand using human cells. We are currently repeating these experiments using mouse primary mammary epithelial cells to reconcile these two datasets.
Our limiting dilution transplantation assays showed decreased regenerative capacity in primary mammary epithelial cells isolated from MMTV-SmoM2 mice relative to wild type, suggesting either a decrease in stem cell frequency, an impaired ability of stem cells to regenerate ductal trees, or both.
Our interpretation of limiting dilution data in conjunction with the mammosphere-formation data is that, in the intact mammary gland in vivo, signaling activation via the MMTV-SmoM2 transgene decreases regenerative stem cell frequency, but increases the survival or activity of division-competent cell types capable of anchorage independent growth. However, it remains possible that the MMTV promoter is not active in the most primitive stem cell (Welm et al., 2005) , which might affect experimental outcome.
With respect to human breast disease, data are accumulating that suggest a role for altered hedgehog signaling in mammary tumorigenesis. An early study found Ptc1 mutations in 2 of 7 human breast cancers (Xie et al., 1997) . Additionally, a Ptch1 polymorphism was linked to increased breast cancer risk associated with oral contraceptive use (Chang-Claude et al., 2003) . More recently, array comparative genomic hybridization (CGH) analyses indicate that genomic loss at the Ptch1 locus was the fourth most commonly detected change among the tumor suppressor genes identified in the study, occurring in 19% of human breast cancers, and 33% of breast cancer cell lines (Naylor et al., 2005) .
However, no mutations in other network components have been identified in breast cancer (Vorechovsky et al., 1999) . A recent immunohistochemical staining study suggested that hedgehog signaling is activated in a majority of human invasive breast cancers based on ectopic expression of PTCH1 and nuclear GLI1 (Kubo et al., 2004) . Further, the hedgehog signaling inhibitor cyclopamine inhibited growth of some breast cell lines in vitro (Kubo et al., 2004; Mukherjee et al., 2006) .
However, the specificity of cyclopamine at the doses required for growth inhibition remains an open question (Mukherjee et al., 2006) .
Our data showing loss of PTCH1 protein expression in ~50% of DCIS and IBC are most consistent with the array CGH results, but differ significantly from the immunohistochemical study by Kubo et al. (Kubo et al., 2004) . In the Kubo study, PTCH1 was not detected in normal tissue, but was detected in 50 of 52 cancers examined. In contrast, we readily detect PTCH1 in normal breast, but expression was reduced or lost in about half of all tumors. The reason for the discrepancy is unclear since both studies used the same rabbit polyclonal antibody, but may be related to the different antigen retrieval strategies used. In our study, we used a second PTCH1 antibody (G-19) to confirm expression patterns in normal human and mouse mammary epithelium. In addition, we used isotypematched rabbit IgG as a negative control (not shown). Since both PTCH1 antibodies yielded consistent expression patterns in both mouse and human tissue, and immunolocalization patterns in mouse were consistent with previous in situ hybridization data, we are reasonably confident in our results. Altered SMO expression in human breast cancer has not been demonstrated previously. Given that SMO was not detectable in normal human or mouse tissue, but was readily detectable in MMTV-SmoM2 mice, we are confident of the specificity of the two antibodies used.
Our observation that SMO protein expression does not colocalize frequently with proliferation markers in either the MMTV-SmoM2 mouse model or in human breast tumors was unexpected. These observations must be reconciled with data suggesting a direct role for hedgehog signaling in normal human stem cell self-renewal (Liu et al., 2006) , and with reports that hedgehog signaling activation appears to increase proliferation directly in other cell types (e.g. (Detmer et al., 2005; Hutchin et al., 2005; MacLean and Kronenberg, 2005; Palma et al., 2005) ). In any case, the similarity in staining patterns of SMO relative to proliferation markers in both the mouse and human models suggests that 21 our MMTV-SmoM2 transgenic model reflects important aspects of human breast tumor biology, and that it will therefore be a useful model for studying the underlying mechanism of hedgehog network regulation of stem/progenitor cell behavior in mammary gland development and breast cancer. Table   4 ). SMO expression is undetectable in normal breast (D), but is detectable in the cytoplasm in ~70% of DCIS (E) and ~30% of IBC (F) (P<.0001, Table4). Primary Mammosphere-forming Efficiency As a Function of Genotype. 
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